What it is
Retatrutide is a man-made peptide (a short chain of amino acids, the building blocks of proteins). It was designed by the drug company Eli Lilly, which also calls it LY3437943. It is described in its trials as a 'triple agonist'. An agonist is a substance that switches a receptor on. Retatrutide switches on the receptors for three natural hormones: GIP, GLP-1 and glucagon.
More on what it is and where it came from
It has been tested in people with obesity, type 2 diabetes, fatty liver disease, knee osteoarthritis and obstructive sleep apnoea. In the trials it was given by injection under the skin and compared with a placebo (a dummy injection).
Retatrutide is not an approved medicine. As of 18 November 2026 we found no approval by the US Food and Drug Administration (FDA), and the FDA's own public page says it has not been found safe and effective for any condition. Products sold online as retatrutide are not the trial drug and have not been checked by any regulator.
Retatrutide was discovered and developed by Eli Lilly and Company. The first study in healthy volunteers finished in 2019, according to the ClinicalTrials.gov registry. Lilly scientists published the discovery work and the first human results in 2022. Two phase 2 trials (mid-stage trials that test different dose levels) were published in 2023. The phase 3 programme (large late-stage trials), called TRIUMPH, began in 2023, and its first results were published in journals in late 2026.
How it is thought to work
GLP-1 and GIP are hormones released by the gut after eating. Medicines that copy them have been shown in other trials to lower blood sugar and reduce appetite. Glucagon is a hormone from the pancreas that raises blood sugar and, in animal studies, raises the amount of energy the body burns. Retatrutide is a single molecule built to act on the receptors for all three.
More on how it works
In laboratory tests reported by Lilly scientists in 2022, the molecule acted on the glucagon and GLP-1 receptors about equally and acted more strongly on the GIP receptor. In obese mice in the same report, it lowered body weight and blood sugar, and the weight loss appeared to come from two things: the animals ate less, and they burned more energy, an effect linked to the glucagon receptor.
Whether the extra energy burning also happens in people has not been shown in the published trials we opened. A separate 2026 study in obese mice by a different research group found large weight loss but no significant change in energy burned. So the exact reason retatrutide produced more weight loss in trials than a placebo is understood in outline, not in detail.
What is established in people
In placebo-controlled trials lasting up to 80 weeks and involving several thousand adults, retatrutide produced large average weight loss (about 17% to 25% in people without diabetes in the main phase 3 trial, and about 12% to 19% in people with type 2 diabetes) and lowered blood sugar. Stomach and gut side effects were common, and more people stopped treatment because of side effects at higher doses. What is not established: safety beyond about two years, whether it lowers or raises the risk of heart attack and stroke (the trial designed to answer this is not due to finish until 2029), how it compares head-to-head with approved obesity medicines, and what happens after stopping. Every trial cited here was paid for by the manufacturer, and retatrutide is not an approved medicine.
What the studies found
12 studies, human trials first. Each links to the paper or registry record.
- Human trial2026
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
This is the largest published retatrutide trial.
Full finding, who was studied, and limits
Who: 2339 adults with obesity and without diabetes, randomised to one of three dose levels or placebo for 80 weeks. Included sub-groups of 574 people with knee osteoarthritis and 243 with obstructive sleep apnoea. Phase 3, double-blind.
This is the largest published retatrutide trial. At 80 weeks average body weight had fallen by 17.6% (lowest dose), 23.7% (middle dose) and 25.0% (highest dose), compared with 3.9% on placebo. In the knee osteoarthritis sub-group, pain scores on a 10-point scale improved by about 1.6 to 1.8 points more than placebo. In the sleep apnoea sub-group, breathing interruptions fell by about 22 to 24 more events per hour than placebo. The most common side effects were in the stomach and gut.
Read with care: Paid for by Eli Lilly, with Lilly employees among the authors. Only the abstract was read, which gives no side-effect numbers. 80 weeks is not long-term for a condition treated for life. Lilly's press release headlined a larger figure (28.3% at the highest dose) that comes from a different way of analysing the data, one that estimates results as if everyone had stayed on treatment; the 25.0% figure counts all participants.
- Human trial2026
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
At 80 weeks average body weight had fallen by 11.9% (lowest dose), 16.8% (middle dose) and 18.8% (highest dose), compared with 5.1% on placebo.
Full finding, who was studied, and limits
Who: 1152 adults with a BMI of 27 or more and type 2 diabetes, at 92 centres in eight countries (mean age 55, 48% female). Randomised to one of three dose levels or placebo for 80 weeks.
At 80 weeks average body weight had fallen by 11.9% (lowest dose), 16.8% (middle dose) and 18.8% (highest dose), compared with 5.1% on placebo. Diarrhoea was reported by 27% to 34% of people on retatrutide and 13% on placebo; nausea by 14% to 28% and 8% on placebo. Low blood pressure and dysaesthesia (abnormal or unpleasant skin sensations) were more frequent with retatrutide. More people stopped treatment for good because of side effects or death in the middle-dose (12%) and highest-dose (8%) groups than in the lowest-dose (4%) or placebo (5%) groups. Seven people died during the trial (six on retatrutide, one on placebo); the investigators judged none of the deaths to be related to the study drug.
Read with care: Weight loss was smaller than in people without diabetes. 84% completed the study drug. Funded by Eli Lilly, with Lilly employees among the authors. Judgements about whether deaths were related to the drug were made by trial investigators.
- Human trial2026
Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity
In TRIUMPH-4, knee pain scores on a 0-to-10 scale fell by 3.96 and 3.74 points in the two retatrutide groups, compared with 2.12 on placebo, and body weight fell by 20.0% and 23.7%, compared with 4.6% on placebo.
Full finding, who was studied, and limits
Who: Two phase 3 trials in adults without diabetes who had painful knee osteoarthritis and a BMI of at least 27: 445 people in TRIUMPH-4 (68 weeks) and 574 in TRIUMPH-1-OA (80 weeks).
In TRIUMPH-4, knee pain scores on a 0-to-10 scale fell by 3.96 and 3.74 points in the two retatrutide groups, compared with 2.12 on placebo, and body weight fell by 20.0% and 23.7%, compared with 4.6% on placebo. Results in TRIUMPH-1-OA were similar. In both trials, serious adverse events (side effects or medical events classed as serious) were more common with retatrutide than with placebo, and the most common side effects were in the stomach and gut.
Read with care: The placebo group also improved by about 2 points, so the extra benefit from the drug was under 2 points on a 10-point scale. The abstract does not say how many serious adverse events there were or what they were. Funded by Eli Lilly. Online-ahead-of-print version.
- Human trial2026
Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea
Participants started with an average of about 56 to 59 breathing interruptions per hour of sleep.
Full finding, who was studied, and limits
Who: Adults with moderate-to-severe obstructive sleep apnoea and a BMI of at least 27: 243 without type 2 diabetes and 448 with type 2 diabetes. Two phase 3 placebo-controlled trials nested inside the larger TRIUMPH-1 and TRIUMPH-2 trials. 80 weeks.
Participants started with an average of about 56 to 59 breathing interruptions per hour of sleep. At 80 weeks, in people without diabetes, interruptions fell by 22.9 to 34.3 events per hour on retatrutide, compared with 9.9 on placebo. In people with diabetes they fell by 19.2 to 25.4, compared with 10.3 on placebo. The most common side effects were in the stomach and gut.
Read with care: These are sub-groups of the two larger trials, not separate populations. The measure is a sleep-study count, not a direct measure of how people felt or of heart outcomes. Funded by Eli Lilly. Online-ahead-of-print version; abstract only.
- Human trial2026
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
At 40 weeks HbA1c had fallen by 1.69, 1.86 and 1.94 percentage points across the three dose levels, compared with 0.81 on placebo.
Full finding, who was studied, and limits
Who: 537 adults with type 2 diabetes not controlled by diet and exercise alone, at 48 sites in the USA, Mexico and India (55% female, mean age 49). Randomised to one of three dose levels or placebo for 40 weeks.
At 40 weeks HbA1c had fallen by 1.69, 1.86 and 1.94 percentage points across the three dose levels, compared with 0.81 on placebo. Body weight had fallen by 11.5%, 13.9% and 15.3%, compared with 2.6% on placebo. Gut side effects were the most frequent, were generally mild to moderate and eased over time. Between 2% and 5% of people on retatrutide stopped because of side effects, compared with none on placebo. No severe low blood sugar was reported. Two people died, both in the lowest-dose group; the report says the deaths were unrelated to the drug.
Read with care: 40 weeks only. Participants had fairly recent diabetes (2.5 years on average) and were not on other diabetes drugs, so results may not apply to people with long-standing disease. The comparison was with placebo, not with another diabetes medicine. Funded by Eli Lilly.
The Lancet 2026;407(10546):2402-2413 (ClinicalTrials.gov NCT06354660) · pubmed.ncbi.nlm.nih.gov
- Human trial2026
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) - company press release only: 'Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C'
COMPANY PRESS RELEASE, NOT PEER REVIEWED.
Full finding, who was studied, and limits
Who: 1949 adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes, according to the press release. Two dose levels or placebo, 80 weeks.
COMPANY PRESS RELEASE, NOT PEER REVIEWED. Lilly reported average weight loss of 21.6% and 22.6% in the two retatrutide groups, compared with 3.2% on placebo, using the analysis that assumes people stayed on treatment. Heart-related events were fewer than expected in all groups. For the broad count of events (death from any cause, heart attack, stroke, heart failure event or a procedure to reopen heart arteries) there were 44 on retatrutide and 52 on placebo. For the narrower count (cardiovascular death, heart attack or stroke) there were 27 on retatrutide and 23 on placebo. Neither difference was statistically clear: the ranges of uncertainty included both benefit and harm. 9.8% and 13.5% of the retatrutide groups stopped because of side effects, compared with 4.8% on placebo.
Read with care: A press release written by the company that makes the drug. It has not been checked by independent reviewers. The trial was designed to measure weight, not heart events, and there were too few events to say whether retatrutide helps or harms the heart. A separate trial of about 10,000 people designed to answer that question is not due to finish its main measurements until 2029, according to ClinicalTrials.gov (NCT06383390).
- Human trial2025
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
Total body fat fell by 15.2% to 26.1% in the middle and higher dose groups, compared with 4.5% on placebo and 2.6% on dulaglutide.
Full finding, who was studied, and limits
Who: 189 participants from the phase 2 type 2 diabetes trial were enrolled in a body-scan sub-study; 103 completed treatment and had both scans. 36 weeks.
Total body fat fell by 15.2% to 26.1% in the middle and higher dose groups, compared with 4.5% on placebo and 2.6% on dulaglutide. The authors reported that the share of weight lost as lean mass (muscle and other non-fat tissue) was similar to that seen with other obesity treatments. In other words, lean mass was lost too, in about the usual proportion.
Read with care: Only 103 of 189 people had complete scans. Body scans cannot tell muscle from other lean tissue or measure strength. Funded by Eli Lilly, with Lilly employees as authors.
- Human trial2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
At 24 weeks liver fat had fallen by 42.9% in the lowest-dose group and by 82.4% in the highest-dose group, compared with a 0.3% rise on placebo.
Full finding, who was studied, and limits
Who: 98 participants from the phase 2 obesity trial who had fatty liver disease with at least 10% liver fat. Randomised to one of four dose levels or placebo for 48 weeks.
At 24 weeks liver fat had fallen by 42.9% in the lowest-dose group and by 82.4% in the highest-dose group, compared with a 0.3% rise on placebo. Liver fat returned to the normal range (under 5%) in 27% to 86% of people on retatrutide, depending on dose, and in none on placebo. The authors reported no signals of liver harm through 48 weeks.
Read with care: A sub-study of 98 people. Its main measure was the amount of fat in the liver, not liver scarring or inflammation. It does not show whether liver disease outcomes improve. Funded by Eli Lilly.
Nature Medicine 2024;30(7):2037-2048 (sub-study of NCT04881760) · pubmed.ncbi.nlm.nih.gov
- Human trial2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
At 24 weeks (the main measure) average body weight had fallen by 7.2% in the lowest-dose group, 12.9% and 17.3% in the two middle dose levels and 17.5% in the highest-dose group, compared with 1.6% on placebo.
Full finding, who was studied, and limits
Who: 338 adults (51.8% men) with obesity, or with overweight plus at least one weight-related condition. People with type 2 diabetes were not the target group. Randomised, double-blind, placebo-controlled, 48 weeks.
At 24 weeks (the main measure) average body weight had fallen by 7.2% in the lowest-dose group, 12.9% and 17.3% in the two middle dose levels and 17.5% in the highest-dose group, compared with 1.6% on placebo. At 48 weeks the figures were 8.7%, 17.1%, 22.8% and 24.2%, compared with 2.1% on placebo. At 48 weeks, 83% of the highest-dose group had lost at least 15% of their weight, compared with 2% on placebo. Stomach and gut side effects were the most common and rose with dose. Heart rate rose with dose, peaked at 24 weeks and then declined.
Read with care: A mid-stage trial of 338 people, split across seven groups, so each group was small. It lasted 48 weeks and did not follow people after they stopped. It was paid for by Eli Lilly, and several authors were Lilly employees.
- Human trial2023
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
At 24 weeks (the main measure) HbA1c, a blood test showing average blood sugar over about three months, had fallen by 0.43 percentage points in the lowest-dose group and by 2.02 points in the highest-dose group, compared with 0.01 on placebo and 1.41 on dulaglutide.
Full finding, who was studied, and limits
Who: 281 adults aged 18 to 75 with type 2 diabetes at 42 US centres (mean age 56, 56% female, 84% White). Compared with placebo and with dulaglutide, an approved GLP-1 medicine. 36 weeks.
At 24 weeks (the main measure) HbA1c, a blood test showing average blood sugar over about three months, had fallen by 0.43 percentage points in the lowest-dose group and by 2.02 points in the highest-dose group, compared with 0.01 on placebo and 1.41 on dulaglutide. At 36 weeks body weight had fallen by 3.19% in the lowest-dose group and by up to 16.94% in the higher-dose groups, compared with 3.00% on placebo and 2.02% on dulaglutide. Mild-to-moderate gut side effects were reported by 35% of people on retatrutide (67 of 190), 13% on placebo and 35% on dulaglutide. There was no severe low blood sugar and no deaths.
Read with care: Small groups (23 to 47 people each), 36 weeks, one country, 84% White participants. 84% completed the study. The lowest dose did not beat placebo on blood sugar. Funded by Eli Lilly.
The Lancet 2023;402(10401):529-544 (ClinicalTrials.gov NCT04867785) · pubmed.ncbi.nlm.nih.gov
- Human trial2022
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
This early safety study found side effects in 63% of people on the drug, 60% on dulaglutide and 54% on placebo, most often in the stomach and gut.
Full finding, who was studied, and limits
Who: 72 adults with type 2 diabetes at four US centres, given rising dose levels, placebo or dulaglutide for 12 weeks.
This early safety study found side effects in 63% of people on the drug, 60% on dulaglutide and 54% on placebo, most often in the stomach and gut. The drug's half-life (the time for the blood level to fall by half) was about six days. At 12 weeks the higher-dose groups had lower blood sugar than placebo, and the highest-dose group had lost about 9 kg more than placebo.
Read with care: Very small and short. 29 of the 72 participants left the study early. Designed to check safety and blood levels, not benefit. Funded by Eli Lilly.
The Lancet 2022;400(10366):1869-1881 (ClinicalTrials.gov NCT04143802) · pubmed.ncbi.nlm.nih.gov
- Animal study2022
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
In cell tests the molecule acted on the glucagon and GLP-1 receptors about equally and more strongly on the GIP receptor.
Full finding, who was studied, and limits
Who: Laboratory receptor tests, obese mice, and a first single-dose study in healthy volunteers, all reported by Eli Lilly scientists.
In cell tests the molecule acted on the glucagon and GLP-1 receptors about equally and more strongly on the GIP receptor. In obese mice it lowered body weight and improved blood sugar control; the weight loss came from eating less plus burning more energy, with the extra energy burning linked to the glucagon receptor. In the first human single-dose study, weight was still lower 43 days after one dose.
Read with care: The mechanism findings come from mice and cells, which often do not carry over to people. The whole paper was written by the company developing the drug. The human part was a small single-dose study.
Cell Metabolism 2022;34(9):1234-1247 · pubmed.ncbi.nlm.nih.gov
Safety findings
- Stomach and gut side effects were the most common in every trial. In the phase 2 obesity trial's registry results, nausea was reported by 28 of 62 people (45%) in the highest-dose group and 8 of 70 (11%) on placebo; vomiting by 12 of 62 (19%) and 1 of 70 (1%). Nausea was less common in a group that started at a lower dose than in a group that started higher at the same final dose (6 of 35 compared with 21 of 35). Source: clinicaltrials.gov
- Heart rate: in the phase 2 obesity trial, heart rate rose with dose, peaked at 24 weeks and declined after that. The abstract does not give the size of the rise, and we could not open the full paper. Source: pubmed.ncbi.nlm.nih.gov
- Serious events in the phase 2 obesity trial (registry results): serious adverse events were recorded in 10 of 267 people on retatrutide and 3 of 70 on placebo. Among people on retatrutide these included one case each of acute pancreatitis (inflamed pancreas), acute gallbladder inflammation, acute kidney injury, heart failure and a prolonged QT interval on a heart tracing, and two strokes in the lowest-dose group. The registry lists events only; it does not say whether the drug caused them. One participant in a retatrutide group died by drowning. Source: clinicaltrials.gov
- In the 1152-person phase 3 trial in people with type 2 diabetes (TRIUMPH-2), diarrhoea affected 27% to 34% on retatrutide and 13% on placebo, and nausea 14% to 28% and 8% on placebo. Low blood pressure was reported in 1% to 6% on retatrutide and under 1% on placebo. Dysaesthesia (abnormal skin sensations) was reported in 4% to 7% on retatrutide and 1% on placebo. Stopping treatment for good because of side effects or death was more frequent in the two higher-dose groups (12% and 8%) than on placebo (5%). Source: pubmed.ncbi.nlm.nih.gov
9 more safety findings
- In two phase 3 knee osteoarthritis trials (445 and 574 people), serious adverse events were more common with retatrutide than with placebo. The abstract gives no numbers or details. Source: pubmed.ncbi.nlm.nih.gov
- COMPANY PRESS RELEASE (not peer reviewed), TRIUMPH-1, 21 May 2026: Lilly reported nausea in 28.6% to 42.4% of people on retatrutide and 14.8% on placebo; vomiting in 10.6% to 25.3% and 4.8% on placebo; dysaesthesia in 5.1% to 12.5% and 0.9% on placebo; urinary tract infections in 7.5% to 8.8% and 5.3% on placebo. 11.3% of the highest-dose group stopped because of side effects, compared with 4.9% on placebo. Source: prnewswire.com
- COMPANY PRESS RELEASE (not peer reviewed), TRIUMPH-4, 11 December 2025: Lilly reported dysaesthesia in 8.8% and 20.9% of the two retatrutide groups and 0.7% on placebo. 12.2% and 18.2% stopped because of side effects, compared with 4.0% on placebo; Lilly said this included people who stopped because they felt they had lost too much weight. Source: prnewswire.com
- Heart attack and stroke: not yet known. In the company's press release on TRIUMPH-3 (people with severe obesity and existing heart disease), the count of cardiovascular deaths, heart attacks and strokes was 27 on retatrutide and 23 on placebo, a difference too small to interpret either way. Not peer reviewed. A dedicated outcomes trial of about 10,000 people is registered with a primary completion date of February 2029. Source: clinicaltrials.gov
- Lean mass: in a body-scan sub-study of people with type 2 diabetes, lean mass was lost along with fat, in a proportion the authors described as similar to other obesity treatments. Source: pubmed.ncbi.nlm.nih.gov
- Liver: in the phase 2a fatty liver sub-study, the authors reported no signals of liver harm through 48 weeks, and rises in a blood ketone marker were not linked to ketoacidosis in any participant. Source: pmc.ncbi.nlm.nih.gov
- Laboratory study, not a trial: in samples of human heart (atrial) muscle taken during heart surgery, retatrutide increased the force of contraction. This shows the drug can act directly on heart tissue in the lab; what it means for people is not known. Source: pubmed.ncbi.nlm.nih.gov
- Unapproved products: a 2026 study of public social media posts by 7823 people who said they were using non-approved retatrutide found the most reported symptoms were increased appetite (17.1%), fatigue (15.2%), nausea (11.6%), insomnia (6.1%) and raised heart rate (4.8%). The authors stressed that product identity, purity and dose could not be checked and that the study cannot show cause, so these are leads for further study only. Source: pmc.ncbi.nlm.nih.gov
- Unapproved products: a 2026 case report described a woman in her mid-20s admitted to hospital with five days of nausea and vomiting that did not respond to anti-sickness drugs, after injections of an unverified product said to contain retatrutide, given in a wellness setting by a person with no medical qualification. Symptoms resolved within a week. A single case cannot prove cause; the product was never tested. Source: pubmed.ncbi.nlm.nih.gov
Rules and status
Not approved. Retatrutide is an investigational (experimental) drug. As of 18 November 2026 we found no FDA approval and no approval by any other regulator.
The full history, with dates
The FDA's public page on unapproved GLP-1 drugs (content current as of 1 October 2026) says retatrutide cannot be used in compounding under federal law, is not a component of any FDA-approved drug, and has not been found safe and effective for any condition. The same page says FDA has warned telehealth companies for marketing unapproved retatrutide, ingredient distributors for selling it to compounders, and outsourcing facilities for repackaging it. It also says FDA has warned companies that illegally sold unapproved drugs containing retatrutide falsely labelled 'for research purposes' or 'not for human consumption', that these were sold directly to consumers for human use with dosing instructions, and that consumers should not buy them because their quality is unknown and they may be harmful. One example is FDA's warning letter of 10 December 2024 to Summit Research Peptides, which named retatrutide as an unapproved new drug despite 'research use only' labelling. On the company side, Lilly said in a press release on 23 July 2026 that it plans to submit retatrutide to FDA for approval in the first quarter of 2027; we found no announcement that it has been submitted. Lilly has also registered a single-patient expanded access programme (ClinicalTrials.gov NCT07629401, first posted 5 June 2026) for adults with severe obesity who meet strict criteria; expanded access is not approval. We found no 2026 change to FDA's position on compounding retatrutide. Retatrutide is not among the six peptides named in the HHS draft enforcement-discretion policy announced on 30 October 2026 (91 FR 68526): Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.
Source: fda.gov (source dated 2026-10-01)
In sport: Not named on the WADA Prohibited List for 2026 (in force from 1 January 2026) or 2027 (in force from 1 January 2027). Class S0 (Non-approved substances) prohibits at all times 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development ...)'. No other section names retatrutide, and this page found no approval of it by any regulator as of 18 November 2026, so S0 applies and it is prohibited at all times. The 2027 List adds peptides as a named example in S0, and WADA's 2027 explanatory note says that even if a peptide is not specifically named on the List, 'it may still be prohibited'. If a regulator approves retatrutide, this would need to be re-checked. Separately, the approved GLP-1 medicines semaglutide and tirzepatide are on WADA's Monitoring Program (watched, not prohibited) for 2026 and 2027; WADA said on 21 September 2026 that the status of GLP-1 receptor agonists would stay unchanged for 2027 while it gathers more data. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| Retatrutide is the most powerful weight-loss drug there is. | In its own trials it produced large average weight loss compared with placebo (about 25% at the highest dose over 80 weeks in the main phase 3 trial). But no head-to-head trial against another obesity medicine has been published. A trial comparing it with tirzepatide (TRIUMPH-5) is registered and had not posted results when we checked. Source: clinicaltrials.gov |
| It is basically approved, or it is legal to buy as a 'research' product. | It is not approved. FDA says it has not been found safe and effective for any condition, cannot be used in compounding, and that FDA has warned companies selling it under 'research' labels. Source: fda.gov |
| Retatrutide sold online is the same as the drug in the trials. | No evidence supports this. The trial drug is made by Eli Lilly and is only supplied through trials and a restricted expanded access programme. FDA says products sold online are of unknown quality, and that illegally marketed versions of drugs in this class could contain the wrong ingredient, too little, too much, or no active ingredient. Source: fda.gov |
| It burns fat without losing muscle. | A body-scan sub-study in people with type 2 diabetes found that lean mass was lost along with fat, in a proportion similar to other obesity treatments. It did not measure muscle strength. Source: pubmed.ncbi.nlm.nih.gov |
| It has mild side effects. | Most reported side effects were graded mild to moderate, but they were common. In the phase 3 trial in people with type 2 diabetes, about a third of people on the two higher doses had diarrhoea, and 8% to 12% stopped treatment for good because of side effects or death, compared with 5% on placebo. In the knee osteoarthritis trials, serious adverse events were more common with retatrutide than placebo. Source: pubmed.ncbi.nlm.nih.gov |
| It protects the heart. | Not shown. Trials found lower blood pressure and blood fats, which are risk markers. Whether that turns into fewer heart attacks and strokes is unknown: the only event data so far are from a company press release and were inconclusive, and the dedicated outcomes trial is not due to finish until 2029. Source: clinicaltrials.gov |
| It cures fatty liver. | In a 98-person sub-study, liver fat on scans fell sharply over 24 weeks. The study did not examine liver scarring or inflammation and does not show that liver disease outcomes improve. Source: pubmed.ncbi.nlm.nih.gov |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match retatrutide's expected mass (average molecular weight about 4731 g/mol; monoisotopic mass about 4728.5 Da, per PubChem). A report that shows only a purity figure, with no mass result, does not prove what the substance is.
- Purity by HPLC (a method that separates a sample into its parts): the report should show the actual chromatogram trace, not just a percentage, along with the method and the date of the test.
- Specificity matters for this compound: semaglutide, tirzepatide and other peptides in this class are different molecules with different masses. The identity test should rule them out, because FDA has warned that products sold in this market may contain the wrong ingredient.
- Amount per vial (peptide content), tested separately from purity. FDA has warned that illegally marketed products in this class can contain too little, too much, or none of the stated ingredient.
- Traceability: a genuine report names the independent laboratory, carries a lot or batch number that matches the label, is dated, and can be confirmed with the laboratory directly.
- A lab report shows what is in one tested sample. It does not make a product an approved medicine, and it says nothing about safety in people.
What is not known
- Long-term safety. The longest published follow-up is 80 weeks (with a 104-week extension reported only in a press release). Nothing is known about years of exposure.
- Heart attack and stroke risk. The TRIUMPH-3 event counts are from a press release and were inconclusive. The outcomes trial (NCT06383390) lists primary completion in February 2029.
- Heart rate. The phase 2 abstract reports a dose-related rise that peaked at 24 weeks and then declined. We could not open the full papers to see the size of the rise, or whether the phase 3 papers report the same pattern.
- Dysaesthesia (abnormal skin sensations) was reported more often with retatrutide than placebo in phase 3. Its cause is not explained in the sources we opened. A possible urinary tract infection signal is discussed in a 2026 journal letter that we could not read in full.
- The knee osteoarthritis paper says serious adverse events were more common with retatrutide than placebo but the abstract gives no numbers. This needs the full text.
- What happens after stopping. A maintenance trial (TRIUMPH-6, NCT06859268) is registered and still running.
- How it compares with approved obesity medicines. The head-to-head trial against tirzepatide (TRIUMPH-5) had no posted results when we checked.
- Whether the glucagon action raises energy burning in people as it did in mice in the original Lilly report. A 2026 mouse study by another group found no significant change in energy burned.
- Whether Lilly has filed with FDA or any other regulator since its July 2026 statement, and whether any country has approved it. We found no approval, but a negative cannot be proven from searches.
- Participant counts differ slightly between sources: TRIUMPH-1 is 2339 in the paper and 2335 in the registry; TRIUMPH-3 is 1949 in the press release and 1946 in the registry.
- Symptoms reported by people using unapproved products (for example increased appetite and insomnia) differ from the trial side-effect pattern. It is unknown whether this reflects the drug, the dose, contaminated or mislabelled products, or who chooses to post.
Sources
All 41 sources
- Phase 2 obesity trial, NEJM 2023 (PubMed). pubmed.ncbi.nlm.nih.gov
- Phase 2 obesity trial, registry record and posted results (NCT04881760). clinicaltrials.gov
- Phase 2 type 2 diabetes trial, Lancet 2023 (PubMed). pubmed.ncbi.nlm.nih.gov
- TRIUMPH-1 phase 3 obesity trial, NEJM 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- TRIUMPH-2 phase 3 trial in obesity with type 2 diabetes, Lancet 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- TRIUMPH-4 and TRIUMPH-1-OA knee osteoarthritis trials, NEJM 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- Sleep apnoea trials, NEJM 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- TRANSCEND-T2D-1 phase 3 diabetes trial, Lancet 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- TRIUMPH programme design paper, Diabetes Obes Metab 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- TRIUMPH-3 registry record (NCT05882045). clinicaltrials.gov
- Company press release, TRIUMPH-2 and TRIUMPH-3 topline, 23 July 2026 (not peer reviewed). prnewswire.com
- Company press release, TRIUMPH-1 topline, 21 May 2026 (not peer reviewed). prnewswire.com
- Company press release, TRIUMPH-4 topline, 11 December 2025 (not peer reviewed). prnewswire.com
- Cardiovascular and kidney outcomes trial registry record (NCT06383390). clinicaltrials.gov
- TRIUMPH-5, retatrutide compared with tirzepatide, registry record (NCT06662383). clinicaltrials.gov
- TRIUMPH-6 maintenance trial registry record (NCT06859268). clinicaltrials.gov
- Expanded access programme registry record (NCT07629401). clinicaltrials.gov
- First-in-human single-dose study registry record (NCT03841630). clinicaltrials.gov
- Fatty liver sub-study, Nature Medicine 2024 (PubMed). pubmed.ncbi.nlm.nih.gov
- Fatty liver sub-study, free full text (PMC). pmc.ncbi.nlm.nih.gov
- Body composition sub-study, Lancet Diabetes Endocrinol 2025 (PubMed). pubmed.ncbi.nlm.nih.gov
- Phase 1b trial, Lancet 2022 (PubMed). pubmed.ncbi.nlm.nih.gov
- Discovery paper, Cell Metabolism 2022 (PubMed). pubmed.ncbi.nlm.nih.gov
- Mouse and hamster study, Obesity 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- Meta-analysis of blood pressure and blood fats in retatrutide trials, High Blood Press Cardiovasc Prev 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- Cardiovascular risk biomarkers in the phase 2 trials, Diabetes Obes Metab 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- Human atrial tissue study, Naunyn-Schmiedeberg's Arch Pharmacol 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- Self-reported adverse effects among social media users taking nonapproved retatrutide, JAMA Network Open 2026 (PMC). pmc.ncbi.nlm.nih.gov
- Case report, BMJ Case Reports 2026 (PubMed). pubmed.ncbi.nlm.nih.gov
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 1 October 2026). fda.gov
- FDA warning letter to Summit Research Peptides, 10 December 2024. fda.gov
- WADA 2026 Prohibited List (in force 1 January 2026). wada-ama.org
- WADA 2026 Monitoring Program. wada-ama.org
- WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
- WADA 2027 Prohibited List, redline version. wada-ama.org
- WADA 2027 Summary of Major Modifications and Explanatory Notes. wada-ama.org
- WADA 2027 Monitoring Program. wada-ama.org
- PubChem compound record, CID 171390338. pubchem.ncbi.nlm.nih.gov
- PubChem substance record from ChemIDplus (name, CAS, UNII, systematic name), SID 471328801. pubchem.ncbi.nlm.nih.gov
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
- Federal Register, 30 October 2026, 91 FR 68526: HHS notice of the draft enforcement discretion policy. govinfo.gov
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.